BACKGROUND: The aim of this study was to validate the Mantle Cell Lymphoma International Prognostic Index in a population-based cohort and to study the relevance of its revisions. DESIGN AND METHODS: We analyzed data from 178 unselected patients with stage III or IV mantle cell lymphoma, registered between 1994 and 2006 in the Eindhoven Cancer Registry. Follow-up was completed up to January 1(st), 2008. Multiple imputations for missing covariates were used. Validity was assessed by comparing observed survival in our cohort with predicted survival according to the original Mantle cell lymphoma International Prognostic Index. A revised model was constructed with Cox regression analysis. Discrimination was assessed by a concordance statistic ('c'). RESULTS: The original Mantle cell lymphoma International Prognostic Index could stratify our cohort into three distinct risk groups based on Eastern Cooperative Group performance status, white blood cell count, lactate dehydrogenase level, and age, with the discrimination being nearly as good as in the original cohort (c 0.65 versus 0.63). A modified model including performance status in five categories (0/1/2/3/4) instead of two (0-1/2-4), the presence of B-symptoms (yes/no) and sex (male/female) in addition to the original variables resulted in a better prognostic index (c 0.75). CONCLUSIONS: The Mantle cell lymphoma International Prognostic Index is a valid tool for risk stratification, comparison of prognosis, and treatment decisions in an unselected Dutch population-based setting. Although the index can be significantly improved, external validation on an independent data set is warranted before broad application of the modified instrument could be recommended.
BACKGROUND: The aim of this study was to validate the Mantle Cell Lymphoma International Prognostic Index in a population-based cohort and to study the relevance of its revisions. DESIGN AND METHODS: We analyzed data from 178 unselected patients with stage III or IV mantle cell lymphoma, registered between 1994 and 2006 in the Eindhoven Cancer Registry. Follow-up was completed up to January 1(st), 2008. Multiple imputations for missing covariates were used. Validity was assessed by comparing observed survival in our cohort with predicted survival according to the original Mantle cell lymphoma International Prognostic Index. A revised model was constructed with Cox regression analysis. Discrimination was assessed by a concordance statistic ('c'). RESULTS: The original Mantle cell lymphoma International Prognostic Index could stratify our cohort into three distinct risk groups based on Eastern Cooperative Group performance status, white blood cell count, lactate dehydrogenase level, and age, with the discrimination being nearly as good as in the original cohort (c 0.65 versus 0.63). A modified model including performance status in five categories (0/1/2/3/4) instead of two (0-1/2-4), the presence of B-symptoms (yes/no) and sex (male/female) in addition to the original variables resulted in a better prognostic index (c 0.75). CONCLUSIONS: The Mantle cell lymphoma International Prognostic Index is a valid tool for risk stratification, comparison of prognosis, and treatment decisions in an unselected Dutch population-based setting. Although the index can be significantly improved, external validation on an independent data set is warranted before broad application of the modified instrument could be recommended.
Authors: Christina Nickenig; Martin Dreyling; Eva Hoster; Michael Pfreundschuh; Lorenz Trumper; Marcel Reiser; Hannes Wandt; Eva Lengfelder; Michael Unterhalt; Wolfgang Hiddemann Journal: Cancer Date: 2006-09-01 Impact factor: 6.860
Authors: Martin Dreyling; Georg Lenz; Eva Hoster; Achiel Van Hoof; Christian Gisselbrecht; Rudolf Schmits; Bernd Metzner; Lorenz Truemper; Marcel Reiser; Hjalmar Steinhauer; Jean-Michel Boiron; Marc A Boogaerts; Ali Aldaoud; Vittorio Silingardi; Hanneke C Kluin-Nelemans; Joerg Hasford; Reza Parwaresch; Michael Unterhalt; Wolfgang Hiddemann Journal: Blood Date: 2004-12-09 Impact factor: 22.113
Authors: Georg Lenz; Martin Dreyling; Eva Hoster; Bernhard Wörmann; Ulrich Dührsen; Bernd Metzner; Hartmut Eimermacher; Andreas Neubauer; Hannes Wandt; Hjalmar Steinhauer; Sonja Martin; Else Heidemann; Ali Aldaoud; Reza Parwaresch; Joerg Hasford; Michael Unterhalt; Wolfgang Hiddemann Journal: J Clin Oncol Date: 2005-01-24 Impact factor: 44.544
Authors: D D Weisenburger; J M Vose; T C Greiner; J C Lynch; W C Chan; P J Bierman; B J Dave; W G Sanger; J O Armitage Journal: Am J Hematol Date: 2000-07 Impact factor: 10.047
Authors: C Schrader; P Meusers; G Brittinger; A Teymoortash; J-U Siebmann; D Janssen; R Parwaresch; M Tiemann Journal: Leukemia Date: 2004-07 Impact factor: 11.528
Authors: Olaf Determann; Eva Hoster; German Ott; Heinz Wolfram Bernd; Christoph Loddenkemper; Martin Leo Hansmann; Thomas E F Barth; Michael Unterhalt; Wolfgang Hiddemann; Martin Dreyling; Wolfram Klapper Journal: Blood Date: 2007-12-12 Impact factor: 22.113
Authors: Saskia A M van de Schans; Liza N van Steenbergen; Jan Willem W Coebergh; Maryska L G Janssen-Heijnen; Dick Johan van Spronsen Journal: Haematologica Date: 2013-09-13 Impact factor: 9.941
Authors: Pavla Veselá; Zbyněk Tonar; David Sálek; Samuel Vokurka; Marek Trněný; Roman Kodet; Mojmír Moulis; Petra Kašparová; Zdeňka Vernerová; Zuzana Velenská; Jan Stříteský; Michal Michal; Ludmila Boudová Journal: Virchows Arch Date: 2014-07-22 Impact factor: 4.064
Authors: Brian G Till; Hongli Li; Steven H Bernstein; Richard I Fisher; W Richard Burack; Lisa M Rimsza; Justin D Floyd; Marco A DaSilva; Dennis F Moore; Olga Pozdnyakova; Sonali M Smith; Michael LeBlanc; Jonathan W Friedberg Journal: Br J Haematol Date: 2015-10-22 Impact factor: 6.998